{
  "docId": "019de070-a5cb-72a4-ac7d-0f26e10cd805",
  "docSlug": "05d98084f9bd31c78a17b84718191aae",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 39,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a split-layout to contrast current late-stage assets with early-stage pipeline candidates.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-a5cb-72a4-ac7d-0f26e10cd805/30",
  "deckHref": "/decks/019de070-a5cb-72a4-ac7d-0f26e10cd805",
  "deckJsonHref": "/decks/019de070-a5cb-72a4-ac7d-0f26e10cd805.json",
  "deckAnchorHref": "/decks/019de070-a5cb-72a4-ac7d-0f26e10cd805#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "1. Interleukin-33 2. Monoclonal antibody 3. Diabetic kidney disease 4. Glucagon-like peptide-1 5. Non-alcoholic steatohepatitis 6. Myeloperoxidase 7. 5-Lipoxygenase-activating protein 8. Coronary artery disease 9. Mineralocorticoid receptor 10. Endothelin receptor 11. Atopic dermatitis (eczema) 12. Interleukin-4 receptor alpha 13. Janus kinase 14. Nerve growth factor 15. Tumour necrosis factor 16. Patatin-like phospholipase domain-containing protein 3 17. Proprotein convertase subtilisin/kexin type 9 18. Antisense oligonucleotide 19. Trial technically classified as Phase II.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ca47f67-0534-498b-ad23-ad5c17fe9b18",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.32,
        "x": 0.65,
        "y": 0.22
      },
      "kind": "table",
      "text": "Phase III new medicines and lifecycle management",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0cbee29e-701c-4f70-bded-9142aca46258",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.49,
        "x": 0.03,
        "y": 0.35
      },
      "kind": "table",
      "text": "Phase I/II new medicines, selected",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d40677a5-45df-4717-98ac-d25b8f361f73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "BioPharmaceuticals: 'What's next' Expanding pipeline, including immunology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7d8dea7-6a5d-4a15-960e-f6dc4ebbe0ab",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "roadmap",
      "slug": null,
      "matchId": "582af46a-955e-471e-9a9b-d3dbe1b41c99",
      "evidence": "The slide organizes drug development assets by clinical phase (I/II vs III).",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 39,
      "from": 19,
      "beatId": "0e550b23-20ef-4625-a839-81a772e4622a",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The document concludes with a call to action and next steps",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 34,
      "from": 30,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "1f01b495-9cdc-4a8a-89ca-3ee50a905914",
      "evidence": "The document presents pipeline events and growth opportunities",
      "position": 1,
      "objective": "Highlighting pipeline events and growth opportunities",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}